The Candriam Luxembourg S.C.A. Sells 39,500 Shares of MacroGenics, Inc. (MGNX), Report finds

The Candriam Luxembourg S.C.A. Sells 39,500 Shares of MacroGenics, Inc. (MGNX), Report finds

Other large investors also recently bought and sold shares of the company. Emerald Advisers Inc. PA raised its stake in MacroGenics by 13.5% in the third quarter. Emerald Advisers Inc. PA now owns 409,942 shares of the biopharmaceutical company’s stock worth $12,261,000 after buying an additional 48,799 shares during the period. BB Biotech AG raised its stake in shares of MacroGenics by 179.8% in the third quarter. BB Biotech AG now owns 1,455,000 shares of the biopharmaceutical company’s stock worth $43,519,000 after buying an additional 935,000 shares during the period. Spark Investment Management LLC raised its stake in shares of MacroGenics by 47.0% in the third quarter. Spark Investment Management LLC now owns 390,600 shares of the biopharmaceutical company’s stock worth $11,682,000 after buying an additional 124,800 shares during the period. Emerald Mutual Fund Advisers Trust raised its stake in shares of MacroGenics by 11.6% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 358,161 shares of the biopharmaceutical company’s stock worth $10,713,000 after buying an additional 37,190 shares during the period. Finally, Teacher Retirement System of Texas raised its stake in shares of MacroGenics by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 3,848 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 466 shares during the period. Institutional investors and hedge funds own 81.74% of the company’s stock.

Candriam Luxembourg S.C.A. cut its position in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 26.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 110,000 shares of the biopharmaceutical company’s stock after selling 39,500 shares during the period. Candriam Luxembourg S.C.A. owned 0.32% of MacroGenics worth $3,290,000 as of its most recent SEC filing.

Shares of MacroGenics, Inc. (NASDAQ:MGNX) traded up 1.74% during mid-day trading on Friday, hitting $19.31. The company had a trading volume of 106,293 shares. MacroGenics, Inc. has a 12-month low of $14.85 and a 12-month high of $33.30. The firm’s 50 day moving average is $19.30 and its 200-day moving average is $25.82. The firm’s market cap is $672.66 million.

A number of equities research analysts have weighed in on MGNX shares. Wedbush restated an “outperform” rating and set a $52.00 price objective on shares of MacroGenics in a research note on Thursday, November 3rd. Zacks Investment Research lowered MacroGenics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 11th. BTIG Research restated a “buy” rating and set a $35.00 price objective on shares of MacroGenics in a research note on Monday, November 7th. SunTrust Banks, Inc. started coverage on MacroGenics in a research note on Monday, December 19th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Roth Capital restated a “buy” rating on shares of MacroGenics in a research note on Wednesday, November 16th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $34.75.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.

Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics, Inc. (NASDAQ:MGNX).

Related posts

Leave a Comment